KCNA2 IgG autoimmunity in neuropsychiatric diseases

BACKGROUND

Autoantibodies against the potassium voltage-gated channel subfamily A member 2 (KCNA2) have been described in a few cases of neuropsychiatric disorders, but their diagnostic and pathophysiological role is currently unknown, imposing challenges to medical practice.

DESIGN / METHODS

We retrospectively collected comprehensive clinical and paraclinical data of 35 patients with KCNA2 IgG autoantibodies detected in cell-based and tissue-based assays. Patients' sera and cerebrospinal fluid (CSF) were used for characterization of the antigen, clinical-serological correlations, and determination of IgG subclasses.

RESULTS

KCNA2 autoantibody-positive patients (n = 35, median age at disease onset of 65 years, range of 16-83 years, 74 % male) mostly presented with cognitive impairment and/or epileptic seizures but also ataxia, gait disorder and personality changes. Serum autoantibodies belonged to IgG3 and IgG1 subclasses and titers ranged from 1:32 to 1:10,000. KCNA2 IgG was found in the CSF of 8/21 (38 %) patients and in the serum of 4/96 (4.2 %) healthy blood donors. KCNA2 autoantibodies bound to characteristic anatomical areas in the cerebellum and hippocampus of mammalian brain and juxtaparanodal regions of peripheral nerves but reacted exclusively with intracellular epitopes. A subset of four KCNA2 autoantibody-positive patients responded markedly to immunotherapy alongside with conversion to seronegativity, in particular those presenting an autoimmune encephalitis phenotype and receiving early immunotherapy. An available brain biopsy showed strong immune cell invasion. KCNA2 autoantibodies occurred in less than 10 % in association with an underlying tumor.

CONCLUSION

Our data suggest that KCNA2 autoimmunity is clinically heterogeneous. Future studies should determine whether KCNA2 autoantibodies are directly pathogenic or develop secondarily. Early immunotherapy should be considered, in particular if autoantibodies occur in CSF or if clinical or diagnostic findings suggest ongoing inflammation. Suspicious clinical phenotypes include autoimmune encephalitis, atypical dementia, new-onset epilepsy and unexplained epileptic seizures.

Renal artery aneurysm in hand-assisted laparoscopic donor nephrectomy: case report

We report a living donor who underwent laparoscopic nephrectomy using a hand-assisted device (HALD). At preoperative arteriography the donor showed a renal artery aneurysm. The patient was a 37-year-old female, 166 cm height, white, weighing 87 kg, HLA identical to the recipient. HALD was indicated due to the better visualization of renal pedicle and greater security in an obese patient. Renal artery aneurysm is a rare condition, with many possible complications. The method proved to be adequate and safe for donor nephrectomy, despite a renal artery aneurysm.

Cancer incidence in humans: relationship to plasma lipids and relative weight

Surveillance was done on cancers in subjects in rural Iowa for 6 years after they participated in a cardiovascular risk factor-screening program. Among 5,565 men and women 20-94 years old at screening, 131 persons were identified as having cancers. Each cancer patient was matched to a control without cancer, and differences in antecedent plasma cholesterol and triglyceride levels and relative weight were sought. Mean relative weight at screening was lower among cancer patients of both sexes than among controls. Plasma cholesterol levels were lower among male patients and higher among female patients than among controls, with the differences more prominent for those less than 60 years old at screening. In males, the lower cholesterol levels occurred only in those with neoplasms developing within 24 months of screening. The higher cholesterol levels among female patients with cancers limited to gonadal hormone-related sites were not time-dependent. Triglyceride levels were not significantly different between cancer patients and controls in any analytic group, but triglyceride levels did closely parallel cholesterol alterations. A minimum of 1% of the cohort had diagnosed cancers before the screening program.